Herein, we show that there is a modest inverse association between changes in hepatic PUFA and plasma and hepatic markers of NASH, i.e., TLR2 agonist and LoxL2 mRNA (r2 = 0.32 and 0.35) respectively (Fig 11). Here, LOXL2 is linked to metabolic dysfunction-associated steatohepatitis.